Ardelyx (ARDX) Prices 20M Share Upized Offering at $6.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- S&P 500, Dow at record highs as Mideast hopes offset SpaceX, AMD drag
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Ardelyx (ARDX) Announces Proposed $80M Public Offering of Common Stock
December 4, 2019 4:57 PM ESTArdelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition,... More
Ardelyx, Inc (ARDX) PT Raised to $10 at SVB Leerink
December 3, 2019 1:14 PM ESTSVB Leerink analyst Ami Fadia raised the price target on Ardelyx, Inc (NASDAQ: ARDX) to $10.00 (from $9.00) while maintaining a Outperform rating.
... MoreArdelyx (ARDX) to Resume Trading at 7:55 am
December 3, 2019 7:37 AM ESTArdelyx (NASDAQ: ARDX) to Resume Trading at 7:55 am
... MoreArdelyx (ARDX) Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis Meets Primary Endpoint
December 3, 2019 7:26 AM ESTArdelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of... More
Ardelyx (ARDX) Halted, News Pending
December 3, 2019 7:22 AM ESTArdelyx (NASDAQ: ARDX) Halted, News Pending
... More